KERLONE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Kerlone, and when can generic versions of Kerlone launch?
Kerlone is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in KERLONE is betaxolol hydrochloride. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betaxolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kerlone
A generic version of KERLONE was approved as betaxolol hydrochloride by EPIC PHARMA on October 22nd, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KERLONE?
- What are the global sales for KERLONE?
- What is Average Wholesale Price for KERLONE?
Summary for KERLONE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 212 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,172 |
| DailyMed Link: | KERLONE at DailyMed |
Recent Clinical Trials for KERLONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centre Hospitalier Universitaire de Saint Etienne | Phase 4 |
US Patents and Regulatory Information for KERLONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | KERLONE | betaxolol hydrochloride | TABLET;ORAL | 019507-001 | Oct 27, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | KERLONE | betaxolol hydrochloride | TABLET;ORAL | 019507-002 | Oct 27, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
